History

AtheroChem was incorporated by PARTEQ Innovations, the technology transfer arm of Queen’s University, (Kingston, Ontario) to develop and commercialize research of Dr. Robert Kisilevsky and Dr. Tom Tam. This work led to a better understanding of the physiological function of serum amyloid A in cholesterol metabolism. The work led to inventions which are the base for AtheroChem’s initial compounds. These early discoveries have been patented by PARTEQ Innovations and are licensed to AtheroChem. Dr. Kisilevsky worked closely with PARTEQ, and specifically Dr. Perry Kim, a former PARTEQ employee, to build a strong scientific foundation for the company. Dr. Kisilevsky is now retired from Queen’s University but remains a scientific advisor to the company.

Dr. Kim recently joined AtheroChem. His work has led to the discovery of small molecules that mimic the cholesterol mobilizing effects of ACLM-19, AtheroChem’s lead peptide molecule. This work is the subject of additional patent filings.

The identification of a new target in the reverse cholesterol transport pathway, and demonstration in accepted animal models that its agents can arrest formation of plaque positions AtheroChem to develop new therapies for atherosclerotic disease. The Company hopes to move from identified candidates to clinical proof of concept during its next stages of development.